Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Brain cannabinoid systems as targets for the therapy of neurological disorders.

Consroe P.

Neurobiol Dis. 1998 Dec;5(6 Pt B):534-51. Review.

PMID:
9974182
2.

AM630 is an inverse agonist at the human cannabinoid CB1 receptor.

Landsman RS, Makriyannis A, Deng H, Consroe P, Roeske WR, Yamamura HI.

Life Sci. 1998;62(9):PL109-13.

PMID:
9496703
3.

Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.

Burkey TH, Quock RM, Consroe P, Ehlert FJ, Hosohata Y, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1997 Oct 8;336(2-3):295-8.

PMID:
9384246
4.

SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.

Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1997 Sep 3;334(1):R1-2.

PMID:
9346339
5.

delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain.

Burkey TH, Quock RM, Consroe P, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1997 Apr 4;323(2-3):R3-4.

PMID:
9128853
6.

AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain.

Hosohata Y, Quock RM, Hosohata K, Makriyannis A, Consroe P, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1997 Feb 19;321(1):R1-3.

PMID:
9083796
7.

AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain.

Hosohata K, Quock RM, Hosohata Y, Burkey TH, Makriyannis A, Consroe P, Roeske WR, Yamamura HI.

Life Sci. 1997;61(9):PL115-8.

PMID:
9284087
8.

The perceived effects of smoked cannabis on patients with multiple sclerosis.

Consroe P, Musty R, Rein J, Tillery W, Pertwee R.

Eur Neurol. 1997;38(1):44-8.

PMID:
9252798
9.

Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception.

Edsall SA, Knapp RJ, Vanderah TW, Roeske WR, Consroe P, Yamamura HI.

Neuroreport. 1996 Jan 31;7(2):593-6.

PMID:
8730837
10.
11.

The human toxicity of marijuana.

Consroe P.

Med J Aust. 1995 Jan 2;162(1):54-5. No abstract available.

PMID:
7845303
12.

A review of recent advances in cannabinoid research and the 1994 International Symposium on Cannabis and the Cannabinoids.

Musty RE, Reggio P, Consroe P.

Life Sci. 1995;56(23-24):1933-40. Review. No abstract available.

PMID:
7776816
13.

Controlled clinical trial of cannabidiol in Huntington's disease.

Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K.

Pharmacol Biochem Behav. 1991 Nov;40(3):701-8.

PMID:
1839644
14.
15.

Enantiomeric cannabinoids: stereospecificity of psychotropic activity.

Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Järbe TU, Hiltunen AJ, Consroe P.

Experientia. 1988 Sep 15;44(9):762-4.

PMID:
3416993
16.

The electromyographic silent period is reduced in individuals at risk for Huntington's disease.

Sandyk R, Bamford CR, Iacono RP, Consroe PF, Gillman MA.

Int J Neurosci. 1988 May;40(1-2):109-10. No abstract available.

PMID:
2969377
17.

Intraspinal opiates for treatment of intractable pain in the terminally ill cancer patient.

Iacono RP, Linford J, Sandyk R, Consroe P, Ryan MR, Bamford CR.

Int J Neurosci. 1988 Jan;38(1-2):111-9.

PMID:
2833456
18.

A cortical vs. subcortical distinction of dementia contrasts with the unifying pathoetiology of Alzheimer's and Parkinson's disease.

Iacono RP, Sandyk R, Consroe PF, Bamford CR.

Int J Neurosci. 1987 Feb;32(3-4):983-5. No abstract available.

PMID:
3596941
19.

Structure-anticonvulsant activity relationships of cannabidiol analogs.

Martin AR, Consroe P, Kane VV, Shah V, Singh V, Lander N, Mechoulam R, Srebnik M.

NIDA Res Monogr. 1987;79:48-58.

PMID:
3125480
20.

Stereochemical requirements for cannabimimetic activity.

Mechoulam R, Lander N, Srebnik M, Breuer A, Segal M, Feigenbaum JJ, Jarbe TU, Consroe P.

NIDA Res Monogr. 1987;79:15-30. Review.

PMID:
3125475
21.

Anticonvulsant and neurotoxic effects of tetrahydrocannabinol stereoisomers.

Consroe P, Mechoulam R.

NIDA Res Monogr. 1987;79:59-66.

PMID:
2830538
22.

Open label evaluation of cannabidiol in dystonic movement disorders.

Consroe P, Sandyk R, Snider SR.

Int J Neurosci. 1986 Nov;30(4):277-82.

PMID:
3793381
23.

Stock differences in the susceptibility of rats to learned helplessness training.

Wieland S, Boren JL, Consroe PF, Martin A.

Life Sci. 1986 Sep 8;39(10):937-44.

PMID:
3489150
24.

Cannabidiol in dystonic movement disorders.

Sandyk R, Snider SR, Consroe P, Elias SM.

Psychiatry Res. 1986 Jul;18(3):291. No abstract available.

PMID:
3749389
25.

The relationship of peripheral trauma and pain to dystonia.

Sandyk R, Consroe P.

J Neurol Neurosurg Psychiatry. 1986 Jul;49(7):845. No abstract available.

26.

L-tryptophan in drug-induced movement disorders with insomnia.

Sandyk R, Consroe PF, Iacono RP.

N Engl J Med. 1986 May 8;314(19):1257. No abstract available.

PMID:
3702925
27.

Convulsant-anticonvulsant properties of delta-9-tetrahydrocannabinol in rabbits.

Fish BS, Consroe P, Fox RR.

Behav Genet. 1983 Mar;13(2):205-11. No abstract available.

PMID:
6305325
28.

The ontogeny of delta-9-tetrahydrocannabinol responsiveness in the rabbit.

Fish BS, Consroe P.

Dev Psychobiol. 1983 Mar;16(2):147-58.

PMID:
6299864
29.

Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice.

Consroe P, Benedito MA, Leite JR, Carlini EA, Mechoulam R.

Eur J Pharmacol. 1982 Sep 24;83(3-4):293-8.

PMID:
6129147
30.

Phencyclidine produces aggressive behavior in rapid eye movement sleep-deprived rats.

Musty RE, Consroe PF.

Life Sci. 1982 May 17;30(20):1733-8.

PMID:
7201554
31.

Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.

Consroe P, Martin AR, Fish BS.

J Med Chem. 1982 May;25(5):596-9.

PMID:
7086846
32.

Propranolol antagonizes phencyclidine-induced hyperactivity and stereotypy in rats.

Consroe P, Boren JL, Hsu CH.

Pharmacology. 1982;24(2):96-104.

PMID:
7200612
33.

Antiepileptic potential of cannabidiol analogs.

Consroe P, Martin A, Singh V.

J Clin Pharmacol. 1981 Aug-Sep;21(S1):428S-436S.

PMID:
7298873
34.

Rabbit behavioral model of marijuana psychoactivity in humans.

Consroe P, Fish BS.

Med Hypotheses. 1981 Aug;7(8):1079-90.

PMID:
6270517
35.

Inheritance of delta 9-tetrahydrocannabinol seizure susceptibility in rabbits.

Fish BS, Consroe P, Fox RR.

J Hered. 1981 May-Jun;72(3):215-6.

PMID:
6268703
36.

Behavioral effects of phencyclidine (PCP) in the dog: a possible animal model of PCP toxicity in humans.

Boren JL, Consroe PF.

Life Sci. 1981 Mar 16;28(11):1245-51. No abstract available.

PMID:
7231047
37.

Tolerance to, and symmetrical cross-tolerance between, cannabinol and delta 9-tetrahydrocannabinol.

Fish BS, Consroe P.

Experientia. 1981 Mar 15;37(3):295-6. No abstract available.

PMID:
6263678
38.

EEG profile of tetrahydrocannabinol seizure susceptible rabbits.

Consroe P, Martin P.

Proc West Pharmacol Soc. 1981;24:11-3. No abstract available.

PMID:
6265948
39.

Acute and chronic antiepileptic drug effects in audiogenic seizure-susceptible rats.

Consroe P, Kudray K, Schmitz R.

Exp Neurol. 1980 Dec;70(3):626-37. No abstract available.

PMID:
7439299
40.

Behavioral pharmacology of tetrahydrocannabinol convulsions in rabbits.

Consroe P, Fish BS.

Commun Psychopharmacol. 1980;4(4):287-91. No abstract available.

PMID:
6268352
41.

Genetic animal models of epilepsy. Introduction.

Consroe P, Edmonds HL Jr.

Fed Proc. 1979 Sep;38(10):2397-8. No abstract available.

PMID:
478016
42.

Audiogenic seizure susceptible rats.

Consroe P, Picchioni A, Chin L.

Fed Proc. 1979 Sep;38(10):2411-6. Review. No abstract available.

PMID:
383516
43.

Activated charcoal--a phencyclidine antidote, or hog in dogs.

Picchioni AL, Consroe PF.

N Engl J Med. 1979 Jan 25;300(4):202. No abstract available.

PMID:
759857
44.

Interaction of cannabidiol and alcohol in humans.

Consroe P, Carlini EA, Zwicker AP, Lacerda LA.

Psychopharmacology (Berl). 1979;66(1):45-50.

PMID:
120541
45.

Tolerance to delta9-tetrahydrocannabinol in adapted and nonadapted rabbits.

Martin P, Consroe P.

Pharmacol Biochem Behav. 1978 Dec;9(6):753-8.

PMID:
746051
46.

Lysergic acid diethylamide antagonism by chlorpromazine, haloperidol, diazepam, and pentobarbital in the rabbit.

Consroe P, Jones B, Martin P.

Toxicol Appl Pharmacol. 1977 Oct;42(1):45-54. No abstract available.

PMID:
929606
47.

Marihuana and epilepsy.

Martin P, Consroe P.

Science. 1977 Sep 23;197(4310):1302. No abstract available.

PMID:
17781985
48.

Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona.

Stillman AS, Huxtable R, Consroe P, Kohnen P, Smith S.

Gastroenterology. 1977 Aug;73(2):349-52.

PMID:
873137
49.

Anticonvulsant interaction of cannabidiol and ethosuximide in rats.

Consroe PF, Wolkin AL.

J Pharm Pharmacol. 1977 Aug;29(8):500-1. No abstract available.

PMID:
19602
50.

Supplemental Content

Loading ...
Support Center